The role and efficacy of pemetinib

Pemigatinib is an oral small molecule targeted drug mainly used to treat advanced cholangiocarcinoma (iCCA), especially those with FGFR2 gene rearrangements or mutations. It is a selective FGFR (fibroblast growth factor receptor) inhibitor that targets and inhibits the FGFR signaling pathway to treat cancer. FGFR2 Gene rearrangements or mutations are common in some patients with cholangiocarcinoma. These mutations allow tumor cells to grow and proliferate uncontrollably. Pemetinib inhibits tumor progression by interfering with this signaling pathway.

Pemetinib reduces the activation of the FGFR signaling pathway by selectively inhibiting the kinase activity of fibroblast growth factor receptors such as FGFR1, FGFR2, and FGFR3. Abnormal activation of FGFR signaling pathway plays an important role in various cancers, especially cholangiocarcinoma. FGFR2 gene rearrangement or mutation can lead to enhanced cell proliferation and angiogenesis. Therefore, inhibiting the activity of FGFR2 can help prevent the proliferation and migration of tumor cells and reduce tumor growth and metastasis.

Pemetinib has shown promising therapeutic effects in clinical trials, particularly in patients with cholangiocarcinoma harboring FGFR2 gene rearrangements or mutations. According to clinical studies, pemetinib can significantly improve patients' overall survival (OS) and progression-free survival (PFS). In a phase III clinical trial, pemetinib showed significant efficacy in patients with cholangiocarcinoma harboring FGFR2 gene rearrangements. Some patients experienced tumor shrinkage, and a large proportion of patients achieved clinical improvement during treatment.

Pemetinib is approved for the treatment of unresectable or metastatic cholangiocarcinoma (iCCA), specifically in patients whose disease has progressed despite chemotherapy and who have FGFR2Gene rearrangements or mutations. The drug can be used as a second-line treatment, providing an effective treatment option especially when patients fail to respond to standard chemotherapy.

In addition, pemetinib is also exploring its potential in other tumor types, including esophageal cancer, non-small cell lung cancer, etc., as a targeted therapy for FGFR mutations or rearrangements.